Schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Intervention group:The usual daily dose atypical anti-psychotic plus 8 mg of ondansetron daily. Intervention 2: The usual daily dose atypical anti-psychotic plus Palacebo daily.
Treatment - Drugs
Intervention group:The usual daily dose atypical anti-psychotic plus 8 mg of ondansetron daily.
The usual daily dose atypical anti-psychotic plus Palacebo daily
Sponsors
Ahvaz Jundishapur University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: a diagnosis of schizophrenia according to DSM-IV-TR; an overall score of 50 or higher on the PANSS scale; 15 or higher negative score in PANSS scale; duration of at least 1 year from onset of the illness. Exclusion criteria: history of sensitivity to ondanstrone; serious medical illness; substance abuse or dependency in recent months; pregnancy; lactation; other simultaneous psychiatric disorders requiring medication; desire to homicide or suicide; having dementia and severe cognitive impairments not bound to schizophrenia; organic brain disorders such as seizure; severe mental retardation and Parkinsonism; consumption of oral antipsychotics during last month or long-acting Injectable forms within three months; Concomitant use of other drugs such as antidepressants; lithium which may interfere in treatment; drug-resistant schizophrenia disorder; lack of response to appropriate dosage and duration of Risperidone.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative sign. Timepoint: at the end of weeks 0 ,3 and 6. Method of measurement: PANSS questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive sign. Timepoint: at the end of weeks 0 ,3 and 6. Method of measurement: PANSS questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMousa Samadi
Jundishapur University of Medical Sciences
Outcome results
None listed